Edition:
United Kingdom

Immunomedics Inc (IMMU.OQ)

IMMU.OQ on NASDAQ Stock Exchange Global Market

13.31USD
18 Jan 2019
Change (% chg)

$-4.78 (-26.42%)
Prev Close
$18.09
Open
$11.87
Day's High
$13.56
Day's Low
$11.57
Volume
7,689,777
Avg. Vol
813,261
52-wk High
$27.32
52-wk Low
$11.57

Chart for

About

Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized... (more)

Overall

Beta: 1.59
Market Cap(Mil.): $1,461.92
Shares Outstanding(Mil.): 125.38
Dividend: --
Yield (%): --

Financials

  IMMU.OQ Industry Sector
P/E (TTM): -- 69.71 33.71
EPS (TTM): -1.44 -- --
ROI: -367.82 8.99 14.48
ROE: -- 10.13 15.99

Immunomedics' cancer treatment fails to win accelerated approval from the FDA

Immunomedics Inc said on Thursday the U.S. Food and Drug Administration declined to grant accelerated approval for its breast cancer treatment, sacituzumab.

18 Jan 2019

Immunomedics' cancer treatment fails to win accelerated approval from the FDA

Jan 17 Immunomedics Inc said on Thursday the U.S. Food and Drug Administration declined to grant accelerated approval for its breast cancer treatment, sacituzumab.

18 Jan 2019

Earnings vs. Estimates